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The Medical Treatment of Systemic Hypertension
BY
R A LP H  K A U N T Z E , m .b.e., m .d., f .r.c.p .
Assistant Physician, and Assistant Physician to the 
Cardiac Department, Guy’s Hospital.
The diastolic blood pressure is the product of the cardiac output and the peripheral arteriolar tone. A resting level in excess of 100 mm. Hg. means that systemic hypertension is present. As 
such it contrasts with systolic hypertension, 
which is the reflection of stroke volume and rigidity of the aorta. It is important to empha­sise this difference, for treatment when necessary is directed to the lowering of diastolic pressure. Bright’s (1827, 1835) original observations 
called attention to the kidney, when cardiac hypertrophy was not associated with valvular disease. Mahomed (1879) was among the first to measure blood pressure in Bright’s disease, 
using a modified Marey’s sphygmograph. To­wards the turn of the century Tigerstedt and Bergmann (1898) isolated from the renal cortex a pressor substance which they named renin. 
It was not, however, until 1934 that Goldblatt et al. produced hypertension in dogs by con­striction of the renal arteries. Subsequently Wilson and Byrom (1939) caused hypertension 
in the rat by constriction of one renal artery. 
If the constriction was short-lived the hyperten­sion was relatively mild and the histological changes in the arteries similar to those in human benign hypertension; the condition was re­
versible. If, however, the constriction was maintained the hypertension became severe and 
was similar to human malignant hypertension, with fibrinoid arteriolar necrosis and intimal proliferation. Removal of the clamped kidney 
did not in these circumstances affect the course of the hypertension, the perpetuation of which 
was attributed to arteriolar changes in the un­damped kidney. Of importance was the finding 
that the clamped kidney showed no arteriolar lesions, presumably as it was protected from the hypertension. It seemed, therefore, that renal ischaemia caused hypertension and that if severe, 
arteriolar lesions resulted and that these, when renal, perpetuated the condition. A mechanism 
involving the interaction of renin and hyper- tensinogen yielding hypertensin, which in turn was broken down by hypertensinase, seemed likely. Yet in chronic hypertension, and apart 
from the early stages of renal artery constriction, no increase in renin or hypertensin in the renal
vein is found. Pickering (1945) has shown in the rabbit, from which one kidney was removed, that the malignant type of hypertension from renal artery constriction persists during survival in spite of nephrectomy, suggesting some extra-renal 
mechanism for its perpetuation. Although the original rise in blood pressure is probably humoral in renal disease, we remain ignorant of the method of its perpetuation; but once the 
blood pressure has been raised for a consider­able time it seems that the pressure regulation becomes fixed at a higher level and remains so, in spite of the removal of the original stimulus 
(aortic coarctation, chromaffinoma, unilateral pyelonephritic kidney).
Excessive circulating nor-adrenaline will pro­duce diastolic hypertension; such can be shown 
experimentally, and in fact occurs in man with phaeochromocytoma. Marked increase in excre­
tion of pressor amines in the urine is present. The hypertension may be sustained rather than paroxysmal. Such a mechanism long continued 
is obviously rare.
Retention of the sodium ion, either from over­dosage of desoxycorticosterone or from an adrenal cortical tumour, in which potassium is 
lost in quantity, as in primary aldosteronism, is associated with reversibly raised blood pressure. Whereas renal ischaemia and sodium retention are both important in hypertension, we remain ignorant of the mechanism underlying primary 
hypertension and that perpetuating the condition 
in the secondary varieties. In consequence, 
treatment is perforce empiric and often unsatis­factory. However, an appreciation of the known factors as well as the gaps in knowledge may 
be of help in the planning of treatment.
Hypertension may be classified as in the table. 
Whether essential hypertension is considered an entity on its own or, as seems more likely and according to Pickering (1955), the upper end 
of a distribution curve, the outcome of genes and environment, a matter of degree rather than 
kind, does not influence the question of treat­ment. but it is of importance that the hypertension is assigned its true aetiology. Hypertension under 40, without a suggestive family story, is not likely to be of the primary variety, and malignant hypertension under 40 is usually nephritic or pyelonephritic. Examination of the urine, the blood chemistry, an intravenous pyelogram and rarely the estimation of the urinary pressor amines will usually suffice for diagnosis. Where there is not a removable cause the severity of the hypertension, no matter the aetiology, must be 
assessed in regard to available treatment.
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Classification oj Systemic Diastolic Hypertension 
(modified jrom Pickering, 1955).
Primary.
Secondary. Renal—
Acute and chronic Type 1 nephritis.
Late Type II nepllritis.
Chronic pyelonephritis.
Obstructive lesions with secondary infection.
Polycystic kidneys.
Vascular lesions of the kidney.
Amyloid kidney.
Radiation kidney.
Endocrine—
Cushing's syndrome.
Aldosteronism.
Phaeochromocytoma.Toxaemia of pregnancy.
Post-toxaemic hypertension.
Arterial—
Coarctation of the aorta.
Polyarteritis nodosa.
Lupus erythematosus diffusa.
The blood pressure may be reduced by seda­
tion, weight reduction, sodium restriction, drugs and rather rarely by lumbo-dorsal sympathec­tomy and bilateral adrenalectomy.
Sedation will mitigate the overlay of anxiety 
and thereby lower blood pressure, but if the 
hypertension is considerable, sedation alone will 
be of limited value. Weight reduction in the obese hypertensive (particularly female) is of 
the utmost importance, but again it will not markedly influence severe hypertension. It is, 
however, to be encouraged. An additional reason is the possible arrest of atheroma. A fat arm gives an unduly high blood pressure read­
ing and some of the pressure lowering from 
diet may be from simple alteration of this factor. The merits of sodium restriction have been over-rated. To be effective the diet should contain not more than 0.5 gm. sodium daily. To maintain a patient on such a diet indefinitely is well-nigh impossible. Compromise whereby salt is avoided in cooking is quite valueless, and ion-exchange resins are difficult to control over 
long periods. This brings us to the hypotensive drugs, which hold so much promise yet so frequently disappoint by their side-effects, but which nonetheless represent a tremendous ad­vance in the treatment of the most severe grades of hypertension. The ideal hypotensive drug 
should be consistently effective by mouth over
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a period of about eight hours and should be free from side-effects. No such preparation is currently available. The hypotensive drugs may be classified as follows:
(a) Those with mainly central action: 
l-hydrazinophlhalazine, dihydrogenated ergot, veratrum viride, thiocyanate and 
Rauwolfia serpentina.
(b) Those with peripheral effect: dibenamine, 
benzylimidazoline and phentolamine.
(c) Those blocking ganglionic transmission:letraethylammonium, pentamethon i u m,
h e x a m ethonium, pentapyrrolidinium. 
“ecolid” and mecamylamine.
From such a list the anti-adrenaline substances 
dibenamine, benzylimidazoline and phentolamine 
can be excluded as unsuitable. Benzylimidazo­
line is used as a peripheral vasodilator and phentolamine as a test of circulating nor-adrena- 
line. Dihydrogenated ergot produces vasodila­
tation with bradycardia, but is effective for a short while only, due to the rapid development of tolerance. The thiocyanates require frequent 
estimation of the blood level, which should be maintained between 8 and 12 mg./lOO ml.; they are erratic in action. The side-effects are rashes, 
nausea, anorexia, drowsiness and confusion. Sodium nitroprusside has similar toxicity. The hypotensive properties of veratrum viride have 
long been known (Douthwaite, 1928), but its 
general use awaited the preparation of stan­dardised, stable, reproducible mixtures of the ester alkaloids. Veratrum yields hypotension, bradycardia and emesis through its action on the central nervous system and the vagal nerve 
endings. Most of the arteriolar dilatation is central in origin, and in practice the von Bezold reflex is unimportant. The bradycardia is 
abolished by atropine, without return of the blood pressure to its former level. With oral administration Kauntze and Trounce (1951) found that the blood pressure could be lowered in two-thirds of cases, yet that in half of these toxic symptoms were an insuperable bar to continuing treatment. In the remaining quarter, although toxic symptoms were not uncommon, 
veratrum appeared to be a fairly satisfactory hypotensive. Review of such patients after 3) years showed the survivors either changed to 
parenteral hexamethonium or with blood pres­sures, which, although not normotensive, were relatively stable without treatment. The patients 
who responded well appeared to be those whose 
hypertension was not rapidly progressive; in
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fact, a group in which treatment is not neces­sarily indicated. The toxic effects of veratrum are unfortunately inseparable from the hypo­
tensive properties, even with the pure alkaloid 
germitrine.
1-Hydrazinophthalazixe 
1-Hydrazinophthalazine (hydrallazine) lowers 
blood pressure and concurrently increases renal 
blood flow'; this is w'ithout change in the glo­merular filtration rate, and is less than propor­tionate to the tachycardia and increased stroke volume. Such may precipitate angina pectoris 
when coronary atheroma is already present 
(Harris and Turner, 1954). Hydrallazine has the interesting property of neutralising certain humoral pressor substances such as hypertensin and pherentasin. Partial tolerance to the drug is rapidly acquired and prolonged oral treatment 
has been unsatisfactory. It is now more usual to give hydrallazine in combination with rauwolfia, hexamethonium or pentapyrrolidinium. Rau­
wolfia as reserpine is given as 1.5-1.0 mg. daily in divided doses for a fortnight; then hydralla­zine is added, beginning with 100 mg. a day and gradually increasing as necessary. Alterna­tively pentapyrrolidinium or hexamethonium is given orally at eight-hour intervals, the latter as the chloride or by subcutaneous injection, then hydrallazine added and gradually increased. Schroeder at al. (1953) have combined oral 
hexamethonium and hydrallazine with success; 
it has the dangers inherent in oral hexame­
thonium. Headache and weakness as well as palpitation from tachycardia due to hydrallazine may he temporarily troublesome. Rarely, with high and prolonged dosage, a condition similar 
to lupus erythematosus diffusa has been reported (Morrow et al., 1953) ; the syndrome has rapidly 
cleared w'ith cessation of hydrallazine.
Rauwolfia serpentina (R eserpine)
Vakil (1940) reported favourably on the hypotensive properties of Rauwolfia serpentina, and Arnold and Bock (1953) stressed the hypo­tension, bradycardia and emotional calm with 
trivial side reactions. Doyle and Smirk (1954), using large doses of reserpine (2 to 3 mg. t.d.s.). 
produced some remarkable falls in diastolic blood pressure, but found nasal and conjunctival con­
gestion, flushing, somnolence, fatigue and de­pression troublesome. The occurrence of de­pression, even with suicidal tendencies, is mainly in those already showing signs of this affective 
disorder, but may crop up suddenly under higher 
dosage in the mentally stable. High dosage is
therefore to be avoided. In my hands 1.5 to 2 mg. reserpine daily has been somewhat un­predictable. The drug is, however, useful in 
augmenting a more potent hypotensive and in its production of bradycardia. It is usual to start with 1.0-1.5 mg. reserpine daily, thence to add hydrallazine or pentolinium orally until adequate control of blood pressure short of side-effects occurs. There is no doubt of the frequent, 
although variable, additive or synergistic action of reserpine; particularly in association with ganglionic blockade, it smoothes out the peaks 
and troughs of hyper and hypotension.
Methonium Compounds
The pharmacology of the methonium salts has been described by Paton and Zaimis (1948), and their circulatory effects by Arnold et al. (1949). They block intra-ganglionic transmis­sion, probably by combination with a receptor 
substance, and thereby cause splanchnic and peripheral arteriolar dilatation. The hypoten­sion is in part orthostatic and may be neutralised 
by binders and bandages; there is associated tachycardia. In recumbency the cardiac output 
is slightly diminished, coronary artery flow unimpaired and renal blood flow after the pre­
liminary decrease returns to normal. Alteration in organ blood flow may persist after the hypo­tensive effect has ceased. The block occurs both in sympathetic and parasympathetic transmission, 
and although the degree of parasympathetic involvement varies with the particular compound, 
it is never sufficiently in abeyance not to cause symptoms.
Hexamethonium
Hexamethonium is a more effective hypoten­sive than tetraethyl ammonium or pentame- thonium. The bromide salt is more soluble than 
the chloride or bitartrate and therefore more 
readily absorbed from the gut; but even with meticulous care in the amount and spacing of 
doses, the rate of absorption is variable. Inter­ference with parasympathetic transmission may diminish the tone of tbe gut to a degree of ileus, which allows continuous and therefore excessive absorption; dangerous hypotension results, in 
which intravenous nor-adrenaline may prove 
ineffectual. Latent pyloric obstruction may become complete; laporotomy has been mis- 
guidedly performed on account of the intestinal obstruction from ileus. Prostatic obstruction 
may also be troublesome from parasympathetic depression. Bromism is a possible danger. No 
such objections can be levelled at subcutaneous
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injection, which in the absence of circulatory 
failure ensures absorption and yields a repro­ducible effect from one to four hours thereafter. I do not think there is now any place for oral hexamethonium in the treatment of hypertension.
The inception of treatment with hexame­thonium entails admission to hospital. During the investigation of renal and cardiac function 
and other special investigations, the blood pressure is recorded four times daily; this gives a base line for subsequent appraisal. A test 
dose of 25 mg. hexamethonium chloride is given intravenously and the response of the patient’s 
blood pressure is recorded in the erect and 
recumbent positions. If the fall in diastolic pressure is trivial, then 50 mg. is given intra­venously the next day. From such findings the patient’s suitability and the dosage are assessed. Usually a start is made with 25 mg. subcu­
taneously at eight-hourly intervals, and this is increased as tolerance develops, the evening 
injection being the largest, until the diastolic pressure erect is between 100 and 110 mm. Hg. three hours after injection. The patient may need to sit or lie for thirty minutes or so after each injection, but should as far as possible be 
propped up or ambulant to benefit from the 
orthostatic hypotension.
It may take a month before stability of dosage is achieved, and as much as 750 mg. may be 
needed during the 24 hours. The patient readily 
learns to give his own injections. Subsequently 
checks at monthly intervals are essential, other­wise the occurrence of hypotensive symptoms gives a rough guide to the efficacy of dosage. Although control in hospital was often good, such was not the case in out-patients in my 
experience.
Pentapyrrolidinium ( P entolinium 
Tartrate)
Pentolinium is a bisquaternary ammonium compound with some structural similarities to hexamethonium. It blocks both sympathetic and 
parasympathetic ganglionic transmission without discrimination. Its hypotensive activity is four 
to six times that of hexamethonium and its effect longer. The clinical use has been reported by Smirk (1953). The variability of intestinal 
absorption makes any sustained control of severe hypertension unlikely when pentolinium tartrate alone is given by mouth. In this connection reserpine may be of help, and when there is no 
urgency treatment should start with reserpine 
0.5 mg. twice daily, the maximal effect of which
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will be apparent in two weeks. Thence pento­linium 20 mg. is given half an hour before breakfast and dinner. The doses are increased by 20 mg. at daily or less frequent intervals, until there is slight faintness on standing three 
hours or so after ingestion. The development of tolerance will soon remedy this, and the dosage will need further adjustment aiming at a diastolic blood pressure erect of about 100 mm. Hg. It must be emphasised that dosage in the 
individual is critical, that absorption is quickened if the drug is taken in solution and fasting, that its effect may persist for twelve hours, in which case hypotensive symptoms may occur 
after breakfast due to cumulation, but that the 
interval between doses in some patients should be only eight hours and that the individual doses may differ in amount, depending on the blood 
pressure readings. Reserpine is continued, for it undoubtedly smoothes out the hypertensive 
peaks. The bowels must be evacuated daily and a regular aperient ensures a margin of safety; but if constipation occurs, then pentolinium must 
be withheld until the condition is rectified. Enemas are to be avoided.
Whereas the success of oral pentolinium, even 
with reserpine, in severe hypertension is specu­lative, by subcutaneous injection it is in my opinion the drug of choice. The effective action lasts about six hours and this can be prolonged 
by solution with ephedrine or combination with oral reserpine 0.5 mg. twice daily. It is usual 
to start with 2.5 mg. pentolinium subcutaneously at 8 a.m.; the afternoon dose is smaller and the 
evening larger. The amounts are gradually increased or the interval shortened from eight to six hours until tolerance develops and the 
diastolic blood pressure is maintained below 120 mm. Hg. and standing is not lower than 80 mm. Hg. Side effects are an inevitable 
concomitant of adequate treatment. Initial treatment is best undertaken in hospital, where 
blood pressure records hourly, standing or sitting, are a great help. Subsequently the patient is re-assessed at weekly and later monthly intervals. This can only be satisfactorily undertaken in a special clinic, but the lack of such ideal facilities 
does not mean that treatment with subcutaneous pentolinium should be withheld.
Mecamylamine
Mecamylamine is a secondary amine, well absorbed from the gut and excreted slowly, mainly (60 per cent, to 80 per cent.) in the 
urine. The hypotensive action lasts from 12 
to 24 hours, and reserpine potentiates this. I
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have used such a combination by mouth in hypertension complicating pregnancy and in very moderate hypertension, with quite gratify­ing results. But in higher dosage side effects 
have been frequent and troublesome.
S idk Effects
Temporary undue hypotension is inevitable 
during treatment, vasodilatation from fever, hot weather or considerable exertion, or depletion 
of the sodium ion may predispose to this. Yawning, dizziness, nausea, amblyopia, facial 
pallor or syncope are indicative of such hypo­
tension and are aggravated by standing still. 
Usually lowering the head in recumbency is sufficient; but if parasympathetic paresis of the gut causing excessive and continuing absorption of the drug, or actual overdosage parenterally 
are responsible, then intravenous nor-adrenaline or methylamphetamine may be necessary and 
neostigmine should be given in ileus.
Paralysis of accommodation tends to lessen with continuing treatment; tinted spectacles or eserine drops may be helpful. Mouth dryness 
is in part relieved by lemon and chewing gum; carbachol has been used. Constipation is not often troublesome with parenteral pentolinium. Previously symptomless pyloric stenosis, prostatic- hypertrophy or glaucoma may become prominent 
during treatment and cause temporary discon­
tinuance. Diminution of libido with ganglionic 
blockade is not uncommon; it is beneficial.
Dissecting aneurysm of the aorta has been 
found at necropsy in nine of 44 hypertensive patients treated with hexamethonium or pento­
linium (Beaven and Murphy, 1956). This high incidence may be due to the very considerable 
daily swings of blood pressure during treatment, when medial degeneration of the aorta is already present.
Indications for Treatment
Before subjecting a patient to a regime which is not merely unpleasant but potentially danger­ous and rarely lethal, it is well to have in mind what advantages both immediate and long term 
are to be gained, and thence to decide the particular merits of treatment. Primary hyper­
tension probably becomes malignant in iess than 1 per cent.; it is less harmful in woman. But where the diastolic level is rapidly rising whilst under observation and in man reaches 130 mm. 
Hg. under age 45, or 140 mm. Hg. in woman, 
the level must be persistently lowered. The
appearance of fluffy retinal exudate presages the 
malignant phase. Such exudates are presumably from oedema and are an expression of the abso­lute height of the diastolic blood pressure and the speed at which it has risen; they may be asso­
ciated with detachment of the retina. They are quite different from the hard, ischaemic exudate arising afresh or following the resolution of 
haemorrhage, and the yellow exudate of diabetes mellitus. That the malignant phase demands immediate hypotensive treatment needs no em­phasis; such treatment first with sympathectomy 
and later with hexamethonium and pentolinium has considerably, although usually only tem­porarily, improved the prognosis. As fibrinoid 
necrosis in the renal arterioles tends presumably to establish a vicious circle of ischaemia, treat­ment should be begun early. Yet even with patients under bi-monthly supervision, consider­able renal damage may be already evident when 
first the malignant phase is diagnosed. Most patients under 45 years have chronic pyelo­nephritis or chronic nephritis underlying their malignant hypertension and tend to have lower 
diastolic pressures than the primary type. Con­siderable renal damage entails much caution over treatment. Hypertensive encephalopathy, beautifully shown by Byrom (1954) to be from diffuse arterial spasm, precipitated by sudden upsurges of blood pressure, needs immediate hypotensive treatment, whether accompanied by 
renal impairment slight or gross.
The basic factors underlying heart failure are excessively increased filling pressure, myocardial failure and increased peripheral resistance, either systemic or pulmonary. Not a few patients 
present with left ventricular failure as the first manifestation of their hypertension. Such will reap much benefit from a lowered blood pressure.
Treatment is imperative in pregnancy with hypertension, both in the production of a living baby and the protection of the mother from 
eclampsia.
In summary these are in my opinion absolute 
indications for treatment with hypotensive drugs:
(1) The malignant phase or the threat of its occurrence (a rapidly rising diastolic level, 
particularly under 45 years and where there 
is not a removable cause).
(2) Hypertensive left ventricular failure.
(3) Hypertensive encephalopathy.
(4) Hypertension in pregnancy.
I have purposely made the indication for treat­
ment severe hypertension, with the exception of 
that in pregnancy. There is no evidence that
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lowering blood pressure in mild or moderate 
hypertension will modify the course of the con­dition. Sudden deterioration in the majority of primary hypertensives is uncommon, and 
unfortunately there is no way of foretelling those 
in whom it will happen. All effective hypoten­sive treatment, other than diet, is attended by- 
distressing side-reactions, and where benefit is unlikely, to subject a patient to such measures is unjustifiable. What of moderate hypertension 
with recurrent headache? Hypertensive head­ache is typically occipital and nuchal in situa­tion, present on waking and disappearing as the day draws on. It is unusual with a diastolic- 
pressure below 120 mm. Hg. and frequently 
absent with a diastolic level of 140. Such head­aches will often respond to sleeping with the head higher, weight reduction and codein; if not, then oral mecamylamine given twice daily 
may be of help. It is a matter of importance 
to distinguish the neurotic headache from the organic, and attention to the history will usually make this obvious.
If moderate hypertension (unless complicated) is not to be treated, it is equally important that where the indications for treatment are clear cut. such treatment should be both continuous and effective.
Type of Treatment
Hypertension in pregnancy, when of slight to moderate severity, that is, with a diastolic up 
to 120 mm. Hg. and where the life of the foetus is in jeopardy, will probably respond well to a combination of oral mecamylamine with reser- pine. This should be continued throughout 
pregnancy and the puerperium. There is no point in prolonging treatment afterwards if the diastolic is relatively fixed. If the hypertension 
is of a progressive nature, this will be apparent during the pregnancy, when control with meca­
mylamine and reserpine will be inadequate.
In severe hypertension, with the complications I have stressed, persistent lowering of the blood pressure is essential for survival, and for most 
of the day the diastolic should be around 100 mm. Hg. At present pentolinium is the most suitable drug for parenteral administration. 
The daily vagaries of intestinal absorption are 
such that effective control over dosage in amount 
and time is only possible by injection. The subcutaneous route is the better. Injections may be thrice or twice in the day and the dose before 
retiring should be the largest. Reserpine is 
given orally for its adjuvant effect. The pre­
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liminary treatment, during which dosage is assessed, is best carried out in hospital, where sufficient blood pressure records are available, the patient is encouraged to be ambulant as far as possible to benefit from the orthostatic hypoten­sion and conversely where medical assurance is available should the blood pressure fall too low. Flat recumbency and the avoidance of heating are sufficient, unless the hypotension is very gross, in which event nor-adrenaline or methylamphe- tamine intravenously will be needed. Peripheral circulatory failure makes intramuscular injection impracticable.
The patient soon learns to give his own in­
jections. The original period in hospital must be adequate for stabilisation of dosage; subse­quent supervision is best in special clinics, where 
ideally the blood pressure range over a whole 
day is recorded. Such is rarely possible, nor is 
control of the blood pressure likely to be abso­
lute, yet in the majority it is adequate.
Wagener and Keith (1924) reported the death 
of their original 14 patients with malignant 
hypertension between one and 44 months after 
diagnosis. Such a prognosis has been remark­
ably changed, first by lumbodorsal sympathec­
tomy and later by the methonium compounds; 
McMichael (1955) reports a two-year survival 
in 43 per cent, of 32 patients treated with 
methonium compared with 7 per cent, of 30 
untreated patients. The main factor in survival 
is that treatment should be instituted before 
renal damage is severe; after two years’ survival 
the chances improve.
Hypertensive encephalopathy can be con­
trolled and hypertensive left ventricular failure 
is alleviated by parenteral pentolinium. The 
outcome in both is mainly dependent on the 
condition of the cerebral or coronary arteries.
Certain severely hypertensive patients with 
adequate renal function cannot be controlled by 
ganglionic blockade. In some I have recom­
mended lumbodorsal sympathectomy, after which 
adequate lowering of blood pressure by 
methonium salts has been obtained. Some 
patients will not tolerate daily injections, and 
for these lumbodorsal sympathectomy may be de­
sirable. I have twice recommended bilateral 
adrenalectomy in patients (both women) with 
unresponsive hypertension and angina decubitus; 
although this has meant substitution therapy, the 
results have been in the circumstances satisfac­
tory.
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